Savara (id:8242 SVRA)
3.36 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:07:33 PM)
Exchange closed, opens in 15 hours 22 minutes
4.02 USD (4.02%)
13.51 USD (13.51%)
-8.20 USD (-8.20%)
-18.64 USD (-18.64%)
-11.11 USD (-11.11%)
236.34 USD (236.34%)
-55.20 USD (-55.20%)
About Savara
Market Capitalization 556.05M
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
| Headquarters (address) |
1717 Langhorne Newtown Road Langhorne 19047 PA United States |
| Phone | 512 614 1848 |
| Website | https://www.savarapharma.com |
| Employees | 37 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | SVRA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.82 - 5.70 |
| Market Capitalization | 556.05M |
| P/E trailing | -10.18 |
| P/E forward | -7.53 |
| Price/Book | 2.78 |
| Beta | 1.02 |
| EPS | -0.430 |
| EPS United States (ID:6, base:3402) | 24.22 |